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A B S T R A C T
This study investigated the effect of a three week supplementation of bilberry extract on glucose metabolism.
Overweight volunteers (n= 16; BMI 31) were given three capsules of either 0.47 g bilberry extract (36% (w/w)
anthocyanins) or placebo per day for three weeks in a double blinded cross over intervention.
The ingestion of the bilberry extract decreased the OGTT AUCi for glucose (20%; p=0.008) but not for
insulin compared with the placebo. There was no change in anti-inflammatory markers (hsCRP, MCP-1, leptin),
vascular health markers (Apo A1, sVCAM-1, sICAM-1), reducing potential/ radical scavenging capacity or faecal
bacterial microbiota. In vitro studies showed that the bilberry extract decreased α-amylase activity
(p < 0.0001), α-glucosidase activity (p < 0.0001) and glucose uptake (p < 0.0001).
This study demonstrates that the ingestion of a bilberry extract over a three week intervention period reduces
postprandial glycaemia without changes in insulin. This is probably due to reduced rates of carbohydrate di-
gestion and/or absorption.
1. Introduction
Dietary strategies for alleviating health complications, such as pre-
mature vascular disease, associated with type 2 diabetes (T2D) and
obesity are actively being pursued as alternatives to pharmaceutical
interventions (Ceriello & Testa, 2009). Such a strategy could comple-
ment other key lifestyle interventions such as avoiding being over-
weight and the need to take regular exercise. The genus Vaccinium (e.g.
blueberry, bilberry, cranberry) has been used traditionally as a source
of folk remedies for established diabetic symptoms.
Berries from this genus are enriched in anthocyanins, a group of
polyphenols recognized for their ability to provide and activate cellular
antioxidant protection and inhibit inflammatory gene expression (Neto,
2007; Tsuda, 2008; Zafra-Stone et al., 2007), activities that may con-
tribute to the efficacy of the Vaccinium genus as ameliorators for type 2
diabetes. For example consumption of a freeze-dried blueberry bev-
erage for an 8week period decreased plasma concentrations of the
cardiovascular risk factors oxidized LDL cholesterol, malondialdehyde
and hydroxynonenal (Basu et al., 2010). In another trial, blueberries
improved insulin sensitivity in obese insulin-resistant men and women
(Stull, Cash, Johnson, Champagne, & Cefalu, 2010). In both these stu-
dies the investigators reported no change in inflammatory markers
following supplementation. However another study with bilberry juice
was shown to decrease plasma markers of inflammation C-reactive
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protein and IL-6 in subjects with increased risk of cardiovascular dis-
ease (Karlsen et al., 2010) and a second study reported a decrease in
inflammation with a diet rich in bilberries (Kolehmainen et al., 2012).
These beneficial responses from human studies (Crespo & Visioli, 2017)
are supported by data that demonstrate long-term beneficial effects of
anthocyanins from mouse models of obesity and diabetes (DeFuria
et al., 2009; Guo, Li, Ling, Feng, & Xia, 2011; Jayaprakasam, Olson,
Schutzki, Tai, & Nair, 2006; Prior et al., 2008, 2010).
There are also a number of studies in vitro and in vivo that suggest
that polyphenols influence carbohydrate digestion and absorption, re-
sulting in improved postprandial glycaemia. Polyphenols form acerola
(Hanamura, Hagiwara, & Kawagishi, 2005; Hanamura, 2006) and vi-
burnum dilatatum (Iwai, Kim, Onodera, & Matsue, 2006) along with
catechins and theaflavns (Matsui et al., 2007) inhibit intestinal α-glu-
cosidase activity. Quercetin glucosides (Cermak, Landgraf, & Wolffram,
2004), polyphenols form acerola (Hanamura, 2006), green tea
(Kobayashi et al., 2000) as well as dietary polyphenols (Johnston,
Sharp, Clifford, & Morgan, 2005; Welsch, Lachance, & Wasserman,
1989) and flavonoids (Song et al., 2002) have all been shown to inhibit
glucose transport in vitro. In humans, several studies have examined
the effect of polyphenols on the post-prandial glycaemic response
(Törrönen et al., 2010). In our previous human intervention study the
ingestion of a bilberry extract given as a single capsule (0.47 g stan-
dardised bilberry extract (36% w/w anthocyanins) followed by an
OGTT in an acute crossover design in volunteers with T2D resulted in a
significant decrease in the OGTT AUCi for both glucose and insulin
compared with the placebo (Hoggard et al., 2013).
Overall evidence suggests that consuming edible berries, particu-
larly from the genus Vaccinium, that have high concentrations of an-
thocyanins could provide a supplementary intervention to improve
glycaemia in subjects with T2D or impaired glucose tolerance (Castro-
Acosta, Lenihan-Geels, Corpe, & Hall, 2016; Coe & Ryan, 2016; Crespo
& Visioli, 2017). The object of this study was to determine the early
mechanisms of action which may be responsible for the reported
changes in glucose metabolism. This study investigated the effect of a
three week supplementation of standardised bilberry extract (36% w/w
anthocyanins) on glucose metabolism in overweight volunteers.
2. Materials and methods
2.1. Subjects
Overweight male and postmenopausal female volunteer subjects
(n=16, BMI 31 SD 4; aged 62 SD 7 years) with (n= 9) or without
(n=7) type 2 diabetes controlled by diet and lifestyle alone (Table 1),
were recruited from the Aberdeen area of the UK. Subjects were only
included if they were not on any special religious or prescribed diet and
had a stable weight. Medical exclusion criteria included chronic ill-
nesses, such as thromboembolic or coagulation problems, thyroid dis-
ease, renal or hepatic disease, severe gastrointestinal disorders, pul-
monary disease (e.g. chronic bronchitis, COPD), alcohol or any other
substance abuse, eating disorders or psychiatric disorders. Volunteers
were also excluded if they were taking oral steroids, tricyclic anti-
depressants, neuroleptics anticoagulants, digoxin and anti-arrhythmics,
or chronically using anti-inflammatories (e.g. high doses of aspirin,
ibuprofen). These criteria were checked with each participant's primary
care physician. All subjects provided informed written consent before
inclusion in the study which was approved by the North of Scotland
Research Ethics Committee (NOSRES). The study was registered at
clinicaltrials.gov number NCT01180712. On all visits, all anthropo-
metric measurements were made following an overnight fast.
2.2. Study design
In a cross-over design, volunteers (n=16) were randomised and
double blinded into two groups matched for BMI as well as age and
given three capsules of either 0.47 g of Mirtoselect® [a standardized
bilberry extract (36% (w/w) anthocyanins)] per day, which equates to
~150 g of fresh bilberries per day, formulated in gelatin capsules or a
control capsule consisting of microcrystalline cellulose in an opaque
gelatine capsule, over a three week period. The opposite procedure was
conducted following a two week washout period. Each volunteer
therefore visited the Human nutrition unit on four occasions when an
overnight fasted plasma blood sample and anthropometric data were
collected. The placebo capsules were not matched for the small amount
of carbohydrate in the bilberry extract. The volunteers were asked to
record what they ate in a food diary over a three day period prior to
each study visit, Food diaries were analysed using NETWISP V3.0
(Tinuviel software) by a trained dietician. Subjects were reimbursed
travelling expenses on completion of the study. Based on previous
published studies we expected between volunteer SD of glucose AUC to
be about 20–22%. Within volunteer variation was expected to be less,
and if it is about half this value then 16 volunteers in a cross-over study
would give us 80% power to detect treatment effects of about 10–12%
(Rebello, Burton, Heiman, & Greenway, 2015).
Although the volunteers consumed their habitual diet while taking
the supplements, syringic acid (35OMe4OHBA), used as a potential
marker of compliance showed a significant difference in the plasma
between placebo and extract (ANCOVA p < 0.001; Appendix Fig. 1).
This hydroxybenzoic acid is ubiquitous in soft fruits and unlike several
of the hydroxycinnamic acids is detected in the plasma and urine fol-
lowing consumption (Russell, Scobbie, Labat, & Duthie, 2009). In ad-
dition to monitor compliance volunteers were asked to record when
they took a capsule and to return any unused capsules to the Human
nutrition unit which were then counted. The capsules were supplied in
excess so that some should have be left over each week.
2.3. Oral glucose tolerance testing (OGTT)
In the evening before the test on each visit the volunteers were
asked to consume the same meal. Volunteers were fasted (10-12hrs)
overnight prior to the OGTT. The last capsule (bilberry extract or pla-
cebo) was ingested in the morning approximately two hours prior to the
venous blood sample being taken at the Rowett Institute.
Venous blood samples were taken through an indwelling cannula
inserted into a forearm vein, at −15, −10, −5 (fasted) and 15, 30, 45,
60, 90, 120, 150, 180 and 240min after consuming 75 g of Polycal
liquid (http://www.nutricia.co.uk). Polycal was selected as the main
Table 1
Baseline characteristics of the overweight non diabetic/diabetic study volun-
teers. Data are mean (SD) for all parameters.
Mean SD
n (male/post-menopausal female) 16 (10/6)
Age 62 7.3
Diet controlled T2D 9
Body mass index (Kg/m2) 31.3 4
Body weight (kg) 93.1 15.1
% Body fat 34.9 9.3
Blood pressure (mmHg)
systolic 137.7 12.8
diastolic 79.4 7
Plasma Cholesterol (mmol/l) 4.6 1.1
Plasma Glucose (mmol/l) 6.2 0.8
Plasma HDL cholesterol (mmol/l) 1.2 0.3
Plasma LDL cholesterol (mmol/l) 2.8 1
Triglycerides (pmol/l) 1.5 0.8
NEFAs (mmol/l) 0.7 0.1
Leptin (ng/ml) 22.3 17.8
Fasting plasma insulin (pg/ml) N/A end point only
HbA1c 6.1 0.5
HOMA-IR N/A
HOMA-beta N/A
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carbohydrate as it is in the form of polysaccharides and this is closer to
normal dietary consumption than glucose only. Movement during the
240min OGTT was kept to a minimum. Plasma glucose concentrations
were measured in triplicate using an automated clinical analyser (Kone
Oyj, Espoo, Finland). Plasma insulin was measured in duplicate using
an ELISA assay (Mercodia, Uppsala, Sweden). The inter- and intra-assay
coefficients of variation were 2.6%–3.6% and 2.8%–3.4%, respectively.
Homeostasis models of assessment of insulin resistance (HOMA, HOMA-
IR and HOMA-beta) was measured using the fasting glucose and insulin
values.
2.4. Metabolic profile
An automated clinical analyser (Kone Oyj) was used for the analysis
of plasma hsCRP, glucose, triacylglycerol, LDL cholesterol, HDL cho-
lesterol, NEFAs, Apo A1, Apo B and cholesterol using commercial kits
(Microgenics Gmbh; Hemel Hempstead, Herts., UK). HbA1c was mea-
sured using an Afinion AS100 Analyser (Abbott, Stirling, UK)
2.5. Mirtoselect®
Mirtoselect® is a standardized extract of bilberries (manufactured by
Indena S.p.A., Milan, Italy), prepared by an industrial process to ensure
a reproducible anthocyanin composition (36%, w/w). Predominant
anthocyanin constituents are delphinidin-3-galactoside, delphinidin-3-
glucoside, delphinidin-3-arabinoside, cyanidin-3-galactoside and cya-
nidin-3-glucoside (Indena datasheet). Other anthocyanins include cya-
nidin-3-arabinoside, petunidin-3-galactoside, petunidin-3-glucoside,
petunidin-3-arabinoside, peonidin-3-galactoside, peonidin-3-glucoside,
peonidin-3-arabinoside, malvidin-3-galactoside, malvidin-3-glucoside,
and malvidin-3-arabinoside. Mirtoselect® also contains other poly-
phenols (phenolic acids, flavonols, proanthocyanidins; ~18%), carbo-
hydrates and aliphatic organic alcohols (~29%), fats (~0.04%), ni-
trogen compounds (~1%), ash (~0.7%), with the remaining 15%
undefined. The main sugar composition of the Mirtoselect® is fructose
13%, glucose 14%; and sucrose 4% (w/w). No side effects of the
Mirtoselect® supplementation were noted.
Local wild bilberries were picked from one season’s growth in one
area from Aberdeenshire, UK. Bilberries were vacuum-freeze dried
(Freezone vacuum Freeze dryer, Labconco, USA) followed by freeze-
milling (Freezer mill Spex CertiPrep 6800, UK) into powder, vacuum-
sealed and stored in −70 °C until further use.
2.6. Plasma ELISAs
Plasma was collected in heparinised EDTA tubes (BD) containing
aprotinin with DPP-IV Inhibitor (Millipore Ltd, Watford Hertfordshire,
UK) added at 10 µl/ml and stored at −70 °C until analysis. Plasma
leptin, MCP-1 and TNFα were measured using the commercial Milliplex
multiplex ELISA kit (HADK2MAG-61K) while plasma sICAM-1, sVCAM-
1 were measured using the commercial Milliplex multiplex ELISA kit
(HSP1MAG-63K). All according to the manufacturer's instructions
(Millipore Ltd, Watford Hertfordshire, UK). All samples were assayed in
triplicate.
The minimum level of detection of leptin was 38 pg/ml and the
intra- and inter-assay coefficients of variation were 10% and 15%, re-
spectively consistent with the manufacturer’s specification. Similar
values for all the other anylates can be found on the Millipore website
(www.millipore.com/).
2.7. Reducing and radical scavenging activity in plasma
The ferric reducing activity of plasma assay (FRAP; Benzie & Strain,
1996) and the Trolox equivalent antioxidant capacity assay (TEAC;
Dragsted et al., 2004) were used to define changes to plasma anti-oxi-
dant capacity. FRAP was assayed in a microplate format, using 6 µl of
plasma to which 18 µl of sterile distilled water and 180 µl of freshly
prepared FRAP reagent (250mM sodium acetate (pH3.6), 1.6mM iron
(III) chloride and 0.83mM 2,4,6-Tri(2-pyridyl)-s-triazine) was added.
Samples were incubated at 37 °C for 4min and absorbance (A593nm;
Dynex Technologies, USA) recorded after 4min and after a further
30min at 37 °C. The difference in A593 between samples and blanks
was calculated and compared to a standard curve of Fe(II) standard
solutions (50–1000 µM). For TEAC analysis a proprietary assay (TEAC
Assay, Sigma CS0970) was used and conducted according to the man-
ufacturer’s instructions. Briefly, 10 µl of plasma was added to 20 µl of
myoglobin solution and 150 µl of ABTS substrate working solution.
Samples were incubated for 5min at 21 °C (as optimised), the reaction
stopped and the A405nm recorded (Dynex Technologies, USA). The an-
tioxidant capacity was reported as trolox equivalents by referral to the
equation obtained from the linear regression of a trolox standard curve.
2.8. Microbial analysis
Faecal samples were collected at the beginning and end of each of
the three-week intervention periods. They were kept at 4 °C and pro-
cessed within 5 h of collection. Each sample was mixed and diluted in
sterile phosphate-saline buffer as described before (Walker et al., 2011).
An aliquot of 450 µl faecal slurry was transferred to Lysing Matrix E
tubes of the FastDNA® spin kit for soil (MB Biomedicals) and stored at
−70 °C until DNA extraction with the same kit according to the man-
ufacturer’s instructions (MB Biomedicals).
Microbiota analysis was carried out for twelve volunteers who had
not been on antibiotics for the three month period prior to providing a
sample and who were willing to provide a sample. DNA was quantified
using a Qubit dsDNA BR Assay kit on a QubitTM 3.0 Fluorimeter
(Thermo Fisher Scientific, Renfrew, UK) as per the manufacturer’s in-
structions. Quantitative real-time PCR (qPCR) was performed with
iTaqTM Universal SYBR® Green Supermix with a CFX384TM Real-time
System (Bio-Rad, Watford, UK) as described before (Vollmer et al.,
2017). Samples were amplified with universal primers against total
bacteria and with specific primers against 21 different microbial
groups. Primers and annealing temperatures are given in Table 2. The
data are expressed as 16S rRNA gene copies per g faeces.
2.9. In vitro analysis
2.9.1. α-amylase assay
Human salivary α-amylase was purchased from Sigma-Aldrich, UK
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Fig. 1. Plasma incremental glucose concentrations following consumption of a
glucose load following three weeks of either the bilberry extract capsule or
placebo control (3× 0.47 g capsules/day) (n= 16 mean +/− SEM)
**P < 0.01, (end point comparison) Change from baseline in the two treat-
ments was compared by analysis of variance in Graphpad Prism.
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(A0521) and the assay was performed using an EnzChek® Ultra Amylase
Assay Kit (E33651), Invitrogen, UK according to the manufacturer’s
instructions.
Briefly all the berry extracts and reagents were prepared in 1X re-
action buffer, provided in the assay kit as instructed. The assay con-
tained a total reaction volume of 100 µl per well in a 96-well plate. 50 µl
of samples were added to 50 µl of 200 µg/ml of DQ substrate solution
(DQ starch from corn, BODIPYL conjugate) while mixing. Each assay
contained the α-amylase enzyme standard curve (50 µl at 0–10mU/ml)
and blank (reaction buffer only, without any enzyme or test samples).
Acarbose at 1mg/ml was taken as the positive inhibitor. The samples
were then incubated at room temperature protected from light for
15min and then read using a 96-well fluorescence microplate reader
(Spectramax Gemini XS- Molecular Devices, USA) at a wavelength of
502/512 nm. For each data point, the background fluorescence was
corrected by subtracting the value derived from the no-enzyme blank.
Samples were read against the standard curve to determine the con-
centration of α-amylase in the test samples.
2.9.2. α-Glucosidase assay
Berry extracts were analysed in triplicate along with no substrate
and no enzyme controls. The enzyme, inhibitor and substrate solutions
were prepared in phosphate buffer (0.1 M; pH 6.9). Yeast α-glucosidase
inhibition was analysed using an end-point assay in a 96-well plate
format. A reaction mixture containing 20 μl of phosphate buffer, 20 μl
of α-glucosidase (0.5 U/ml) and 20 μl of berry extracts of varying
Table 2
Quantitative PCR primers and annealing temperatures used in this study.
Target group Primer Primer sequence 5′-3′ Annealing temperature Reference
total bacteria UniF GTGSTGCAYGGYYGTCGTCA 60 Fuller et al. (2007)
UniR ACGTCRTCCMCNCCTTCCCTC
Bacteroides spp. G-Bfra-R-Fmod GCTCAACCKTAAAATTGCAGTTG 63 Reichardt et al. (2018)
Bac708Rmod GCAATCGGRGTTCTTCGTG
Prevotella spp. g-Prevo-Fmod CRCRCRGTAAACGATGGATG 65 Reichardt et al. (2018)
BacPreRmod TTGAGTTTCACCGTTGCCGG
Ruminococcaceae1 sg-Clept-F GCACAAGCAGTGGAGT 60 Vollmer et al. (2017)
sg-Clept-Fm2 GCACAAGCGGTGGATT
sg-Clept-R3 CTTCCTCCGTTTTGTCAA
Faecalibacterium prausnitzii2 FPR-2F GGAGGAAGAAGGTCTTCGG 60 Ramirez-Farias et al. (2009)
Fprau645mR AATTCCGCCTACCTCTGCACT
Ruminococcus bromii Rflbr730F GGCGGCYTRCYGGGCTTT 60 Salonen et al. (2014)
RbromR CAACTTTCCCCGAAGGGCACCTA
Ruminococcus albus/bicirculans 400Fmod1 GACTGCCGTTGACAAAAC 60 Salonen et al. (2014)
RalbR CCTACAATCCGAACTAAGACTGC
Ruminococcus flavefaciens/callidus/
champenellensis
400Fmod1 GACTGCCGTTGACAAAAC 60 Salonen et al. (2014)
Rfla+R CCTRCAATCTGAACTGGGACAA
Oscillibacter/Oscillospira-related1 Osc370F1 GGCAATGGACGCAAGTCTGACC 60 Walker et al. (2011)
Osc370F2 GGCAATGGGCGCAAGCCTGACC
Osc455R1 ATTCGTCAGGTACCGTCTTCTRCTC
Osc455R2 ATTCGCCAGGTACCGTCTTCTACTC
Osc455R3 ATTCAAGDGGTACCGTCTTCTRCTC
Osc455R4 ATTCTAGAGGTACMGTCTTCTRCTC
Osc455R5 GTTTTCAGGGTACCGTCTTCTGCTC
Negativicutes (Cluster IX)1 IX552F GTTGTCCGGAATYATTGGGC 63 Reichardt et al. (2014)
IX854R2A ATTGCGTTAACTCCGGCACA
IX854R2G ATTGCGTTAACTCCGGCACG
Roseburia/Eubacterium rectale group RrecF GCGGTRCGGCAAGTCTGA 63 Ramirez-Farias et al. (2009)
Rrec630mR CCTCCGACACTCTAGTMCGAC
Eubacterium hallii EhalF GCGTAGGTGGCAGTGCAA 60 Ramirez-Farias et al. (2009)
EhalR GCACCGRAGCCTATACGG
Anaerostipes hadrus SSC2F2 CTTTAGTAGCCAGCATATAAGG 60 Louis, Young, Holtrop, and Flint
(2010)SSC2R TTGCTCACTCTCACGAGGCT
Coprococcus eutactus CeutFext/L2-50Fext TTCCAGTAGCCAGCAGTMAGAT 63 Reichardt et al. (2018)
CeutR CAATCCGAACTGAGACAGCC
Dorea spp. DoreaF GCAGCTAACGCAATAAGCAG 60 Reichardt et al. (2018)
DoreaR CATTACGAAGCGGTCATCG
Eubacterium eligens EelF CGCACAATGTTGCATGACAT 63 Chung et al. (2016)
EelR CTTAGTCAGGTACCGTCACTA
Blautia spp. BlautiaF2 CGCGTGAAGGAAGAAGTATC 63 Reichardt et al. (2018)
BlautiaR2 GAGCCTCAACGTCAGTTACC
Lactobacillus spp. LAC-1 AGCAGTAGGGAATCTTCCA 60 Walter et al. (2001)
Lab 0677 CACCGCTACACATGGAG Heilig et al. (2002)
Bifidobacterium spp. BifF TCGCGTCYGGTGTGAAAAG 60 Fuller et al. (2007)
g-Bifid-R GGTGTTCTTCCCGATATCTACA
Bifidobacterium adolescentis Bif164F GGGTGGTAATGCCGGATG 60 Ramirez-Farias et al. (2009)
BiADO-2 CGAAGGGCTTGCTCCCAGT
Desulfovibrio spp. Dsv691F CCGTAGATATCTGGAGGAACATCAG 63 Fite et al. (2004)
Dsv826R ACATCTAGCATCCATCGTTTACAGC
Enterobacteria EnterobactDmod2F GACCTCGCGAGAGCA 60 Hansen et al. (2012)
Enter1432mod CCTACTTCTTTTGCAACCCA
Methanogenic Archaea Met630F GGATTAGATACCCSGGTAGT 60 Walker et al. (2011)
Met803R GTTGARTCCAATTAAACCGCA
Primer references: Chung et al. (2016), Fite et al. (2004), Fuller et al. (2007), Hansen et al. (2012), Heilig et al. (2002), Louis et al. (2010), Ramirez-Farias et al.
(2009), Reichardt et al. (2014), Reichardt et al. (2018), Salonen et al. (2014), Vollmer et al. (2017), Walter et al. (2001), Walker et al. (2011).
1 Where more than one forward or reverse primer is given, all primers are used together at equimolar concentrations.
2 The primers exhibit some cross-reactivity with Subdoligranulum variabile.
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concentrations within the physiological range was prepared and pre-
incubated for 15min at 37 °C, 3mM pNPG (40 μl) was then added to the
mixture as the substrate. The reaction was stopped by adding 150 μl of
sodium carbonate (0.2M) to the reaction mixture. Absorbance was read
at 405 nm by a microplate reader (μQuant™ Microplate
Spectrophotometer, BioTek Instruments Inc. USA) and compared to a
control which had 200 μl of buffer solution only. Acarbose was used as
an inhibitor at a concentration of 1mg/ml for the assay. The α-gluco-
sidase inhibitory activity was expressed as inhibition percentage (%)
and was calculated as follows;
=inhibition A Control nm A Sample nm
A Control nm
% (405 ) (405 )
(405 )
X100
where; ΔA= Individual absorbance recorded at 405 nm after sub-
tracting from the blank.
2.9.3. Glucose uptake
Cell culture
CaCo-2 cells obtained from ATCC were cultured in Eagle’s minimum
Essential medium, 12-662 (EMEM; Lonza), supplemented with 10%
fetal bovine serum (Gibco), 100 IU/ml penicillin G, 100 μg/ml strep-
tomycin sulfate (Sigma-Aldrich) and 0.2mM L-glutamine G7513
(Sigma-Aldrich). Cells were cultured in a humidified 37 °C incubator
with 5% CO2.
Glucose uptake
The amount of glucose uptake in CaCo-2 cells was measured using
the Glucose Uptake-Glo Assay Kit (Promega) according to the manu-
facturer’s instructions. Cells were seeded in a 12 well plates and cul-
tured for 19–20 days post confluence. Cells were incubated in serum
free media overnight (16 hrs), the following day culture medium was
removed and cells were washed twice with PBS. The cells were in-
cubated in glucose free media containing the treatments for 2 hrs prior
to the addition of glucose. Freshly prepared 10mM 2-deoxyglucose was
added and incubated for 20min. The uptake process was stopped, 75 µl
transferred to a 96 well white walled plate (Gibco) then neutralized and
detection reagent added, protocol carried out as per manufacturer’s
instructions. Luciferase activities were measured on Tecan plate reader.
The rate of glucose uptake was analyzed according to the manu-
facturer’s instructions.
Both berry extracts used in this study were not cytotoxic to the
CaCo-2 cells at all the concentrations used. This was determined using
by the CellTiter-Blue (CTB) cell viability assay kit (Promega-G8081,
UK) (Data not shown).
2.10. Statistical analysis
The area under the curve (AUC) was calculated using the trapezoid
approximation. For the incremental version (AUCi), only the extent of
interpolated values above baseline contributed.
Treatment effects were assessed by Analyses of variance of the
endpoint of each intervention period, with terms for volunteer (random
effect), period (1st or 2nd) and treatment (placebo or extract) and
baseline values as a covariate.
For the in vitro analysis all the samples were run in triplicates for
each experiment, and the results were presented as a mean ± standard
error. Statistical analysis was performed using GraphPad Prism 7.0 for
Windows. The data was analysed using One-Way-Analysis of Variance
(ANOVA) to compare the groups and Tukey’s test was performed to
account for multiple comparisons.
Microbiota analysis: The endpoint data was analysed by Analysis of
Variance with volunteer as random effect and supplement (prebiotic or
placebo) as fixed effect, and with the corresponding baseline mea-
surements as covariate. Order (order in which the two supplements
were given) and gender or diabetic status were included as fixed effects
to investigate whether these modified the response to treatment.
3. Results
3.1. Volunteers
The mean body weight of the volunteers remained stable during the
study: 93.2 (SD 14.8) kg on visit 1 compared with 93 (SD 15.4) kg, 93.6
SD (SD 14.8) kg and 94.0 (SD 14.8) kg on visits 2, 3 and 4. Similarly the
percentage body fat of the volunteers also remained relatively stable
during the study: 34.9% (SD 9.3%) on visit 1 compared with 36.1% (SD
8.6%), 35.8% (SD 8.9) and 36.7% (SD 8.7%) on visits 2, 3 and 4. The
order in which the capsules were taken (control vs bilberry extract) did
not significantly influence any variable. There was no significant dif-
ference between any of the variables measured, the diabetic status or
sex of the volunteers. Therefore all subsequent data is presented as one
group ingesting the bilberry extract or the placebo control over the
three week intervention period.
The averages for dietary intake and nutrient composition readings
obtained from repeated four day diet records (for three days prior to
and on the day of each study visit) compiled by the study subjects
taking either three weeks of bilberry extract treatment or three weeks of
placebo are shown in (Table 3). No significant changes were recorded in
energy intake or any of the other macronutrients measured when the
volunteers were on the bilberry extract compared to when the volun-
teers were on the placebo (Table 3). There was no significant change in
fasting plasma glucose levels in volunteers taking the bilberry extract
compared with the control (Table 4).
3.2. Oral glucose tolerance test (OGTT)
3.2.1. Plasma glucose
The ingestion of the bilberry extract over the three week interven-
tion period resulted in lower OGTT venous plasma glucose AUCi com-
pared with placebo with a 20% decrease in the glucose (656 vs 523;
p=0.008; Fig. 1). Eleven of the sixteen volunteers showed a decrease
in plasma glucose AUCi when taking the bilberry extract compared with
the placebo (data not shown). The incremental plasma glucose con-
centrations were significantly lower at 90min after taking the bilberry
extract compared with the placebo control (p < 0.01, Fig. 1). Although
the differences in glucose following the OGTT was only significant at
90mins the differences in the curves suggest that the bilberry extract is
having a greater effect on glucose in the second half of the curve
Table 3
Averages for dietary intake and nutrient composition readings obtained from
repeated four day diet records (for the three days prior to and on the day of
each study visit) compiled by study subjects taking either three weeks of bil-
berry extract treatment or three weeks of placebo. Data are presented as
average ± SEM. n=16 (ns=no significant difference). Comparisons were
based on t-tests carried out in Graphpad Prism.
Study week Placebo Extract t-test
Energy (KJ) 0 9480 ± 466 8580 ± 476 ns
3 9890 ± 500 9680 ± 464 ns
Energy (Kcal) 0 2260 ± 111 2040 ± 113 ns
3 2352 ± 118 2304 ± 110 ns
Protein (g) 0 96 ± 5 87 ± 9 ns
3 97 ± 6 92 ± 5 ns
Fat (g) 0 90 ± 7 83 ± 4 ns
3 92 ± 5 96 ± 5 ns
Carbohydrates (g) 0 266 ± 16 230 ± 18 ns
3 276 ± 17 260 ± 16 ns
Sucrose (g) 0 99 ± 6 89 ± 9 ns
3 103 ± 9 103 ± 8 ns
Starch (g) 0 150 ± 13 136 ± 11 ns
3 167 ± 12 151 ± 10 ns
Fibre (g) 0 24 ± 2 24 ± 2 ns
3 26 ± 2 24 ± 2 ns
Alcohol (g) 0 13 ± 4 10 ± 4 ns
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compared with the placebo.
3.2.2. Plasma insulin
When comparing the OGTTs at the end of the three week inter-
ventions (bilberry extract intervention vs placebo intervention) the
ingestion of the bilberry extract had no significant effect on the venous
plasma insulin compared with placebo (p=0.72; Fig. 2).
3.3. Lipid metabolism
The bilberry extract had no effect on fasting plasma concentrations
of cholesterol, HDL-cholesterol, LDL cholesterol, NEFA or triglyceride
compared with placebo control (Table 4).
3.4. Inflammatory adipokines/markers
The bilberry extract had no effect on fasting plasma concentrations
of the inflammatory adipokine MCP-1, TNF-α, leptin, hsCRP (Table 4)
compared with placebo control.
3.5. Markers of cardiovascular health
The bilberry extract had no effect on fasting plasma concentrations
of Apo A1, Apo B, sVCAM-1 or sICAM-1 (Table 4) compared with
placebo control.
3.6. Oxidative state reducing activity and radical scavenging potential
Similarly there was no effect of the bilberry extract on the reducing
activity or radical scavenging features of plasma as measured by FRAP
and TEAC assays compared with placebo (Table 5).
3.7. Microbial analysis
Microbiota composition at the start and end of each intervention
period was determined by qPCR against total bacteria and 21 microbial
families, genera and species belonging to Bacteroidetes, Firmicutes,
Actinobacteria, Proteobacteria and Archaea. No effect of treatment was
found for either total bacterial abundance or the microbial groups ex-
amined (Fig. 3).
3.8. In vitro analysis
The concentration of extracts used for the in-vitro analysis were
based on Cai et al. (2011) who measured the anthocyanins and meta-
bolites in the urine by HPLC-MS/MS following a single dose of the same
bilberry extract used our human intervention.
Table 4
Markers of glucose, lipid metabolism, vascular health and inflammatory adipokines /markers taken fasted at the being of each intervention and at the end of each
three week intervention period following the ingestion of three capsules a day of either bilberry (Vaccinium myrtillus L.) extract or the placebo. Values are means of
triplicate replicates of all sixteen subjects, with standard errors. Change from baseline in the two treatments was compared by analysis of variance in Graphpad Prism.
Placebo Extract
Baseline 1 SD Change over 3 weeks SD Baseline 2 SD Change over 3weeks SD p
Glucose Glucose (mmol/L) 6.34 0.76 0.03 0.44 6.42 0.96 −0.18 0.48 ns
Lipid metabolism Cholesterol (mmol/L) 4.65 1.21 0.02 0.20 4.49 1.11 −0.12 0.38 ns
HDL Chol (mmol/L) 1.21 0.35 0.02 0.09 1.18 0.35 −0.07 0.18 ns
LDL-Chol (mmol/L) 2.79 1.00 −0.10 0.29 2.71 1.01 −0.15 0.24 ns
NEFA (mmol/L) 0.67 0.12 −0.08 0.20 0.69 0.20 0.03 0.21 ns
TRIGLY (mmol/L) 1.54 0.74 −0.19 0.42 1.55 0.72 0.03 0.41 ns
Vascular health Apo A1 (g/L) 1.31 0.17 0.00 0.18 1.30 0.20 −0.01 0.13 ns
Apo B (g/L) 0.84 0.29 −0.04 0.08 0.82 0.26 −0.02 0.15 ns
sVCAM-1 (pg/ml) 442,000 170,000 684 152,000 434,000 129,000 6468 65,294 ns
sICAM-1 (pg/ml) 118,000 87,000 9730 50,500 108,000 40,300 3670 13,593 ns
Inflammatory adipokines/markers Leptin (pg/ml) 23,500 20,800 1760 6250 21,400 15,000 −1600 7720 ns
MCP-1 (pg/ml) 178 65.3 14.2 30.5 177 56.8 12.0 41.6 ns
TNFα (pg/ml) 5.89 2.24 0.14 1.39 6.68 4.28 0.64 3.23 ns
hsCRP (mg/L 4.04 5.29 0.60 4.67 3.16 4.74 −1.56 6.43 ns
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glucose load following three weeks of bil-
berry extract or placebo control capsule
(3× 0.47 g capsules/day) (n=16 mean
+/− SEM). **P < 0.01, (end point com-
parison) Change from baseline in the two
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3.8.1. Bilberry extract and freeze dried wild bilberries inhibit salivary α-
amylase
We determined if bilberry extract and freeze dried wild bilberries
can inhibit the activity of human salivary α-amylase in vitro. Both
bilberry extract and wild freeze dried bilberries extracts showed a dose-
dependent inhibition of human salivary α-amylase (ANOVA
P < 0.0001; Fig. 4). The bilberry extract showed 61% (P < 0.0001),
57% (P < 0.0001) and 55% (P=0.0001) inhibition of human salivary
α-amylase at 66, 6.6 and 0.66 μg/ml respectively, while freeze-dried
wild freeze dried bilberries showed 78% (P < 0.0001), 73%
(P < 0.0001) and 68% (P=0.0001) inhibition of human salivary α-
amylase at the same respective concentrations. Both the extracts
showed greater inhibition of salivary α-amylase than the commercial
inhibitor acarbose at 1mg/ml (31%, P= 0.003). No activity was ob-
served with either no enzyme or no substrate controls.
3.8.2. Bilberry extract inhibits yeast α-glucosidase but not the freeze dried
wild bilberries
We determined the effects of bilberry extract and freeze dried wild
bilberries on the activity of yeast α-glucosidase derived from S. cerevi-
siae. The bilberry extract significantly inhibited yeast α-glucosidase
activity (ANOVA P < 0.0001; Fig. 5). The inhibition of yeast α-glu-
cosidase activity by the bilberry extract was dose-dependent (77% in-
hibition at 66 μg/ml; (P < 0.0001); 45% inhibition at 13.2 μg/ml;
(P < 0.0001) and 17% inhibition at 6.6 μg/ml; (P=0.003). At the
same concentrations, freeze dried wild bilberries showed no effect on
yeast α-glucosidase activity (Fig. 2B). Acarbose, the known inhibitor of
yeast α-glucosidase activity inhibited the enzyme activity by 47%
(P≤ 0.001) at 1mg/ml. No activity was observed with no enzyme and
no substrate controls.
3.8.3. Bilberry extract and freeze dried wild bilberries inhibit 2DG uptake
We then determined the effect of Bilberry extract and freeze dried
wild bilberries extract on 2DG uptake in vitro. Bilberry extract and wild
freeze dried bilberry extract extracts showed an inhibition of 2DG up-
take (ANOVA P < 0.0001; Fig. 6) in CaCo-2 cells. Bilberry extract
showed 61% (P < 0.0001) inhibition of 2DG uptake in CaCo-2 cells at
6.6 μg/ml, but not at 0.66 or 0.066 μg/ml respectively, while freeze-
dried wild freeze bilberry extract showed 73% (P < 0.0001), 50%
(P < 0.0001) and 32% (P= 0.0001) of inhibition of 2DG uptake in
CaCo-2 cells at the respective concentrations tested. As a control, the
glucose transporter inhibitor, Phloretin (1mM) showed a 63% inhibi-
tion of 2DG uptake in the CaCo-2 cells (P < 0.0001).
4. Discussion
The present study shows that the ingestion of concentrated bilberry
extract as three capsules per day containing concentrated bilberry ex-
tract over a three week period reduces the post-prandial glycaemic
response in overweight volunteers compared to an inert placebo cap-
sule. The bilberry extract over the same period had no effect on post
prandial plasma insulin compared with the control. We should say that
we cannot totally rule out an acute effect of the capsule on the glucose
metabolism (Hoggard et al., 2013) as the last capsule was taken ap-
proximately two hours before the OGTT. Huang, Park, Edirisinghe, &
Burton-Freeman (2016) have shown significantly reduced glucose
concentrations over the 10-h day when strawberries were given 2 h
before a meal compared to consuming strawberries with the meal
suggesting it may be important for strawberry constituents, such as
anthocyanins, to be absorbed and be available prior to maximal nu-
trient absorption, possibly priming cellular processes for managing the
impending metabolic stress resulting in improved nutrient management
Table 5
Plasma concentrations for ferric-reducing ability of plasma (FRAP) Trolox equivalent antioxidant capacity (TEAC) taken at the being of each intervention and at the
end of each three week intervention period following the ingestion of three capsules a day of either bilberry (Vaccinium myrtillus L.) extract or the placebo. Values
are means of triplicate replicates of all sixteen subjects, with standard errors. Change from baseline in the two treatments was compared by analysis of variance in
Graphpad Prism.
Placebo Extract
Baseline 1 SD Change over 3weeks SD Baseline 1 SD Change over 3weeks SD p
FRAP (Fe II mmol/L) 1430 177 20 187 1510 178 15 168 ns
Teac mmol Trolox equivalents/L 469 126 16 149 470 143 18 94 ns
Fig. 3. Faecal microbiota composition before and after three weeks of either the bilberry extract or placebo control (3× 0.47 g capsules/day) determined by
quantitative PCR targeting the 16S rRNA gene of different microbial groups. Average and standard error of 12 volunteers. Treatment order was found not to modify
the response and no significant differences were found between bilberry extract or placebo for any of the microbial groups determined. Change from baseline in the
two treatments was compared by analysis of variance in Graphpad Prism.
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and reduced inflammatory burden.
One study has shown that consuming a smoothie supplemented with
blueberries (from the same genus as bilberry) for six weeks increased
insulin sensitivity as determined by hyperinsulinemic –euglycemic
clamp in obese and pre-diabetics when compared to the control group
consuming a placebo smoothie (Stull et al., 2010). Another study
showed that subjects with T2D that consumed capsules containing
80mg of anthocyanins (purified from bilberry and blackcurrant) taken
twice a day for 24 weeks had a significant improvement in HOMA_IR
(i.e. increased insulin sensitivity) (Li, Zhang, Liu, Sun, & Xia, 2015).
However some studies have reported no changes in insulin sensitivity
between the berry and placebo groups (Basu et al., 2010; Stull et al.,
2015).
We looked at a shorter three week intervention period to determine
the early effects of the bilberry extracts.
Bilberries are enriched in anthocyanins recognized for their ability
to provide and activate cellular antioxidant protection, inhibit in-
flammatory gene expression, and consequently protect against oxidant-
induced and inflammatory cell damage and cytotoxicity (Neto, 2007;
Tsuda, 2008; Zafra-Stone et al., 2007). In light of this we investigated in
the effects of the bilberry extract on the inflammatory markers hsCRP,
MCP-1, TNFα, and leptin that play a role in the recruitment of mono-
cytes due to the low grade inflammation associated with obesity
(Nakamura, Fuster, & Walsh, 2014). However in this study we did not
see any changes in plasma levels of hsCRP, MCP-1, TNFα or leptin due
to the ingestion of the bilberry extract compared with the control. Si-
milarly we could not detect any alterations in plasma TEAC or FRAP
values, both indicative of changes with activities/capacities frequently
linked to changes in antioxidant status within environments such as
plasma (Apak et al., 2016). Antioxidant status assay in themselves not
de facto link to nor should they infer an effect on oxidative stress.
Nevertheless, the absence of change reported here indicates that the
extract does not dramatically affect antioxidant capacity.
T2D is closely linked with cardiovascular health and in light of this
we looked for changes in plasma markers of cardiovascular heath
(Harding, Pavkov, Magliano, Jonathan, & Edward, 2019). We observed
no changes in Apo A1, Apo B1, sVCAM-1 or ICAM-1 due to the ingestion
of the bilberry extract compared with the control.
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Fig. 4. Effect of bilberry and wild freeze dried bil-
berries extract on salivary α-amylase activity Effect
of bilberry and wild freeze dried bilberries extract
(66, 6.6 and 0.66 μg/ml) and the commercial in-
hibitor acarbose (1mg/ml) on salivary α-amylase
activity. Enzyme activity was determined as a per-
centage of the control. All the samples were run in
triplicate and are expressed as percentage
activity ± SD Experiments were repeated in-
dependently at least three times on separate days
with the similar results. Statistical analysis was done
by one-way analysis of variance of Tukey’s multiple
comparison tests. Values without a common letter
are significantly different (P < 0.05). AC: Acarbose,
BE: Bilberry extract, WT: Wild freeze dried bilber-
ries. Change from baseline in the two treatments was
compared by analysis of variance in Graphpad
Prism.
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Fig. 5. Effect of bilberry and wild freeze
dried bilberries extract on α-glucosidase
activity Effect of bilberry and wild freeze
dried bilberries extract (66, 6.6 and 0.66 μg/
ml) and the commercial inhibitor agarose
(1mg/ml) on α-glucosidase activity.
Enzyme activity was determined as a per-
centage of the control. The 95% methanol
control was shown not significantly dif-
ferent from the control. All the samples were
run in triplicate and are expressed as per-
centage activity ± SD. Experiments were
repeated independently at least three times
on separate days with the similar results.
Statistical analysis was done by one-way
analysis of variance of Tukey’s multiple
comparison tests. Values without a common
letter are significantly different (P < 0.05).
AC: Acarbose, MC: 95% methanol control,
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treatments was compared by analysis of
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Disruption of the ecological equilibrium in the gut has been asso-
ciated with several pathological processes, including obesity and its
related comorbidities, with diet being a strong determinant of gut mi-
crobial balance. In vitro studies suggested that polyphenols exert anti-
microbial effect on detrimental bacterial species while favouring the
growth of beneficial bacteria. Species potentially beneficial, as
Lactobacillus spp. and Bifidobacterium spp., have been reported to in-
crease in the presence of polyphenols especially anthocyanin whereas
the growth of potentially detrimental species, such as Enterobacteria, is
decreased (Anhê et al., 2015; Duda-Chodak, Tarko, Satora, & Sroka,
2015; Faria, Fernandes, Norberto, Mateus, & Calhau, 2014; Jamar,
Estadella, & Pisani, 2017). We have seen no change in the faecal bac-
terial microbiota in a sub population of twelve volunteers with the
addition of the bilberry extract compared with the placebo control. It is
possible that the three week intervention period in our study is simply
too short a period to see changes in the faecal bacterial microbiota.
Although dietary fibre has been shown to affect post-prandial glu-
cose (Wood, 2007), the bilberry extract used in each capsule only
contains 18mg of dietary fibre (15mg in soluble form). This small
quantity is unlikely to explain the reduced glycaemic response.
It has been suggested that berry polyphenols inhibit α-glucosidase,
the enzyme responsible for the digestion of sucrose to glucose in the
intestinal epithelium. Two anthocyanins cyanidin-3-rutinoside
(Adisakwattana et al., 2004) and cyanidin-3-galactoside
(Adisakwattana, Charoenlertkul, & Yibchok-Anun, 2009) have been
shown in vitro as inhibitors of α-glucosidase. Cyanidin-3-galactoside is
present in bilberries (Buchert et al., 2005) and cranberries (Wilson
et al., 2008), and has shown a synergistic effect with acarbose
(Adisakwattana et al., 2009). Acarbose is used as an inhibitor of α-
glucosidase in the treatment of diabetes. Also proanthocyanidins have
shown potent α-glucosidase inhibitory activity (Kumar, Narwal, Kumar,
& Prakash, 2011; Schäfer & Högger, 2007). The anthocyanins in the
bilberry extract are well documented (Cai et al., 2011; Cooke et al.,
2006) and include both cyanidin-3-galactoside and proanthocyanidins.
Similarly some studies have suggested that berry polyphenols inhibit
salivary α-amylase the enzyme responsible for the digestion of starch
into maltose and dextrin (Grussu, Stewart, & McDougall, 2011).
We used polycal, which is composed of complex carbohydrates
(glucose syrup, maltodextrin), as the glucose load in this study for the
OGTT. Therefore the reduced postprandial glycaemia in response to the
three week bilberry extract intervention may be due in part to a re-
duction in the breakdown of carbohydrates. To investigate this further
we looked at the effect in vitro of the bilberry extract as well as a freeze
dried wild bilberry extract on both α-amylase activity and α-glucosi-
dase enzyme activity. The bilberry extract at physiological concentra-
tions (Cooke et al., 2006) inhibits the human salivary α-amylase and as
well as the yeast α-glucosidase enzyme activity which supports the
theory that the breakdown of carbohydrates in digestion is a key me-
chanism of action in the decrease of postprandial glucose. The freeze
dried wild bilberry extract at the concentrations tested only decreased
the human salivary α-amylase enzyme activity. The bilberry extract is
higher in anthocyanins compared to the freeze dried wild bilberry ex-
tract which may account for the difference but this is something that
needs further investigation. We are currently investigating the effects of
in vitro digested berries and the individual polyphenols which are
present in the bilberries to try and identify the active polyphenols.
There is also evidence that polyphenols and bilberry anthocyanins
can affect the absorption of glucose across the intestine (Baron et al.,
2017; Zou et al., 2014). This is thought to be mediated by active Na-
dependent transport via sodium glucose co-transporter 1 (SGLT1) and
facilitated Na-independent transport via GLUT2 (Levin, 1994). The
Na+-dependent SGLT1-mediated glucose uptake appears to be in-
hibited by several phenolic acids (e.g. chlorogenic, ferulic and caffeic
acids) (Welsch et al., 1989) as well as by glycosides of quercetin
(Cermak et al., 2004). The glucose transport by GLUT2 was inhibited by
the flavonols quercetin and myricetin (Johnston et al., 2005; Song et al.,
2002). These polyphenols and flavonols with inhibitory activity against
intestinal glucose uptake are common polyphenolic constituents of
berries (Määttä-Riihinen, Kamal-Eldin, Mattila, González-Paramás, &
Törrönen, 2004). To investigate this further we looked at the effect in
vitro of the bilberry extract as well as the freeze dried wild bilberry
extract on the uptake of fluorescently labelled 2-deoxyglucose uptake.
Both the bilberry extract as well as the freeze dried wild bilberry in-
hibited glucose uptake in human CaCo-2 cells compared to the un-
treated control cells.
Thus both reduced breakdown of carbohydrates and lowered in-
testinal absorption of carbohydrates appear to be key events leading to
the improved glycaemic excursion we observe in this study.
5. Conclusion
In conclusion, the ingestion of a concentrated bilberry extract over a
three week period at amounts that can be easily tolerated produces a
reduced AUCi postprandial glycaemia in overweight volunteers in
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response to an OGTT. This suggests that this is the initial effect of the
ingestion of the bilberry extract over the three week intervention period
which may lead to changes in insulin response (Stull, 2016). We show
that the reduced rates of carbohydrate digestion and/or absorption are
the most likely cause of the observed decreases in glycaemic response.
In our intervention study no changes in faecal gut microbiota,
plasma inflammatory/oxidative markers or markers of cardiovascular
health were observed in volunteers taking bilberry extract compared
with the control which suggests that these are potentially later events to
the observed changes in glucose metabolism.
The use of berry polyphenols as phytochemicals capable of lowering
the glycaemia response to carbohydrates not only in subjects with
diabetes but also in those with impaired glucose tolerance control may
prove to be useful in helping control blood sugar. Such a strategy could
complement other lifestyle interventions such as avoiding being over-
weight and the need to take regular exercise.
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